Sophie Tsai is a Scientist in Patient-Centered Outcomes and Real-World Evidence & Data Analytics, located in Pharmerit’s Bethesda, MD office. She has experience in patient and stakeholder engagement, patient advocacy group (PAG) engagement, patient/caregiver/physician preference studies (including discrete-choice experiment, best-worst scaling, time-trade-off), strategic evaluation of patient-reported outcomes (PRO) instruments for use in a clinical trial, and PRO instrument development, spanning over a variety of therapeutic areas, including oncology, rare diseases, infectious diseases, pediatric diseases, and neurodevelopmental diseases.
Prior to joining Pharmerit, Sophie completed her post-doctoral fellowship with the Center for Health Services and Outcomes Research (CHSOR) at the Johns Hopkins Univserity. During which time, she partnered with the U.S. Food and Drug Administration (FDA) and patient advocacy groups (such as Parent Project Muscular Dystrophy and the Foundation for Prader-Willi Research) to engage stakeholders and the disease community in preference research. She led focus groups at an FDA public workshop to determine patient and FDA reviewer priorities and preferences in prosthetic devices.
Her research focuses on applying stated-preference methods to prioritize clinical outcomes associated with the disease and preferences for the benefits and risks of treatments. In her manuscript titled, “Research as an Event: a Novel Approach to Promote Patient-focused Drug Development,” she introduced a novel and resource-efficient method to partner with patient groups and engage patients in research. She holds a Medical Doctor degree from Taipei Medical University and a Masters in Health Science in Health Economics degree at Johns Hopkins University, and she is a Master of Business Administration (MBA) candidate at the Johns Hopkins University.